GlassScriptPhysician profile
Mary Ann Lester
NPI 1750713269
$1,258.63
in general payments reported to CMS, 2019-2025
20 companies · $93.28 in 2025
The $93.28 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $395 · 2022: $313 · 2023: $255 · 2024: $203 · 2025: $93.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $352.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $104.46 | 2023-2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $93.80 | 2023 | Rebyota |
| Novo Nordisk INC | $90.67 | 2021-2024 | Wegovy |
| Amgen INC. | $87.23 | 2021-2025 | Repatha, Otezla |
| Abbott Laboratories | $82.25 | 2021-2022 | |
| Abbvie INC. | $80.07 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.96 | 2021-2024 | Jardiance, Tradjenta |
| Dexcom, INC. | $47.33 | 2021-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $30.94 | 2021-2024 | Trintellix |
| Optinose US, INC. | $30.83 | 2021 | |
| Pfizer INC. | $30.18 | 2021 | |
| Genentech USA, INC. | $28.13 | 2021 | |
| Alkermes, INC. | $25.55 | 2025 | Vivitrol |
| Glaxosmithkline, LLC. | $21.94 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.61 | 2023 | Quviviq |
| La Jolla Pharmaceutical Company | $20.23 | 2024 | Xerava |
| Janssen Pharmaceuticals, INC | $19.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.58 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.06 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.